Abstract
Mouse mammary tumor viral superantigens (vSAgs) are produced by germline-encoded proviruses and infectious viruses (for reviews see refs. 1,2. Like other superantigens, they interact with class II major histocompatiblity complex (MHC) proteins and trigger T-cell proliferation via recognition of particular variable elements (Vβ) of the T-cell receptor (TCR). Prior to the discovery of their viral origin, the provirus-encoded vSAgs were referred to as Mls (minor lymphocyte stimulatory) antigens (3). Unlike the bacterial superantigens, which are produced as small soluble proteins, the vSAgs are produced as membrane glycoproteins that transit the exocytic pathway and undergo partial proteolytic processing by cellular endoproteases (4). Proteolytic processing appears to be necessary for vSAgs to activate T cells (5-7), and available data suggest that a soluble carboxy terminal processing product may be sufficient for vSAg function (8). The vSAgs require class II MHC proteins to be presented to T cells (9, although not necessarily for surface expression (8).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Acha-Orbea, H. and MacDonald, H. R. (1995) Superantigens of mouse mammary tumor virus. Ann. Rev. Immunol. 13, 459–486.
Acha-Orbea, H., Finke, D., Attinger, A., Schmid, S., Wehrli, N., Vacheron, S., et al. (1999) Interplays between mouse mammary tumor virus and the cellular and humoral immune response. Immunol. Rev. 168, 287–303.
Festenstein, H. (1973) Immunogenetic and biological aspects of in vitro lymphocyte allotransformation (MLR) in the mouse. Transplant. Rev. 15, 62–88.
Winslow, G. M., Kappler, J., and Marrack, P. (1997) Structural features of MMTV superantigens. In Superantigens: Structure, Biology, and Relevance to Human Disease. Leung, D., Huber, B., and Schlieverts, P. (eds.), Marcel Dekker, New York, NY, pp. 37–60.
Mix, D. and Winslow, G.M. (1996) Proteolytic processing activates a viral superantigen. J. Exp. Med. 184, 1549–1554.
Winslow, G. M., Cronin, T., Mix, D., and Reilly, M. (1998) Redundant proteolytic activation of a viral superantigen. Mol. Immunol. 35, 897–903.
Denis, F., Shoukry, N. H., Delcourt, M., Thibodeau, J., Labrecque, N., McGrath, H., et al. (2000) Alternative proteolytic processing of mouse mammary tumor virus superantigens. J. Virol. 74, 3067–3073.
Reilly, M., Mix, D., Reilly, A. A., Ye, Y. Y., and Winslow, G. M. (2000) Intercellular transfer of a soluble viral superantigen. J. Virol. 74, 8262–8267.
Beutner, U., McLellan, B., Kraus, E., and Huber, B. T. (1996) Lack of MMTV superantigen presentation in MHC class II-deficient mice. Cell. Immunol. 168, 141–147.
Scherer, M. T., Ignatowicz, L., Winslow, G., Kappler, J. W., and Marrack, P. (1993) Super antigens: bacterial and viral proteins that manipulate the immune system. Ann. Rev. Cell Biol. 9, 101–128.
Acha-Orbea, H., Held, W., Waanders, G. A., Shakhov, A. N., Scarpellino, L., Lees, R. K., and MacDonald, H. R. (1993) Exog-enous and endogenous mouse mammary tumor virus superantigens. Immunol. Rev. 131, 5–25.
Held, W., Shakhov, A. N., Waanders, G., Scarpellino, L., Luethy, R., Kraehenbuhl, J.-P., et al. (1992) An exogenous mouse mammary tumor virus with properties of Mls-1a. J. Exp. Med. 175, 1623–1633.
ArdavÍn, C., Waanders, G., Ferrero, I., Anju’ere, F., Acha-Orbea, H., and MacDonald, H.R. (1996) Expression and presentation of endogenous mouse mammary tumor virus superantigens by thymic and splenic dendritic cells and B cells. J. Immunol. 157, 2798–2794.
Webb, S. R. and Sprent, J. (1990) Induction of neonatal tolerance to Mlsa antigens by CD8+T cells. Science 248, 1643–1646.
Winslow, G. M., Scherer, M. T., Kappler, J. W., and Marrack, P. (1992) Detection and biochemical characterization of the mouse mammary tumor virus 7 superantigen (Mls-1a). Cell 71, 719–730.
Winslow, G. M., Marrack, P., and Kappler, J. W. (1994) Processing and Major Histocompatibility Complex binding of the MTV7 superantigen. Immunity 1, 23–34.
Krummenacher, C. and Diggelmann, H. (1993) The mouse mammary tumor virus long terminal repeat encodes a 47 kDa glycoprotein with a short half-life in mammalian cells. Mol. Immunol. 30, 1151–1157.
McMahon, C. W., Bogatzki, L. Y., and Pullen, A. M. (1997) Mouse mammary tumor virus superantigens require N-linked glycosylation for effective presentation to T cells. Virology 228, 161–170.
Subramanyam, M., McLellan, B., Labrecque, N., Sekaly, R., and Huber, B. T. (1993) Presentation of the Mls-1 superantigen by human HLAclass II molecules tomurineT cells.J. Immunol. 151, 2538–2545.
Mishell, R. I. and Dutton, R. W. (1967) Immunization of dissociated spleen cell cultures from normal mice. J. Exp. Med. 126, 423–442.
Mohan, N., Mottershead, D., Subramanyam, M., Beutner, U. and Huber, B. T. (1993) Production and characterization of an Mls-1-specific monoclonal antibody. J. Exp. Med. 177, 351–358.
Gollub, K. J. and Palmer, E. (1991) The physiologic expression of two superantigens in the BDF1 mouse. J. Immunol. 147, 2447–2454.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc.
About this protocol
Cite this protocol
Winslow, G. (2003). Flow Cytometric Detection of MMTV Superantigens. In: Krakauer, T. (eds) Superantigen Protocols. Methods in Molecular Biology™, vol 214. Humana Press. https://doi.org/10.1385/1-59259-367-4:045
Download citation
DOI: https://doi.org/10.1385/1-59259-367-4:045
Publisher Name: Humana Press
Print ISBN: 978-0-89603-984-1
Online ISBN: 978-1-59259-367-5
eBook Packages: Springer Protocols